Novo Nordisk & Eli Lilly Cut Obesity Drug Prices in China Amidst Market Competition

Obesity Drug Price Reductions in China

• 📉 Novo Nordisk and Eli Lilly are lowering prices for their leading obesity drugs, Wegovy and Mounjaro, in China.
• 🎯 This strategic move aims to strengthen their positions in China's rapidly expanding market, which is experiencing rising obesity rates.

Specific Price Adjustments and Market Context

• 📊 List prices for the highest doses of Wegovy have reportedly been cut by up to 48% in some Chinese provinces.
• 🗓️ Mounjaro's prices are also set to decrease starting January 1st.
• ⚠️ Both companies face increasing competition and challenges, including the expiration of Novo Nordisk's patent for semaglutide in China in 2026.

Market Growth and Global Strategy

• 📈 China's population, projected to have over 65% overweight or obese individuals by 2030, presents a significant growth opportunity.
• 🌍 Novo Nordisk also recently slashed Wegovy prices in India by up to 37% and both companies agreed to cut US prices in November, indicating a global pricing strategy adjustment.